Switching from Divalproex to Lamotrigine in Bipolar II Disorder
Direct Recommendation
Initiate lamotrigine at 25 mg daily while maintaining full-dose divalproex 500mg twice daily, then slowly escalate lamotrigine over 6-8 weeks to 200mg daily before beginning a gradual taper of divalproex by 250-500mg decrements every 1-2 weeks. 1, 2
Lamotrigine Titration Schedule
The titration of lamotrigine must be slow to minimize the risk of serious rash, which occurred in 9-13% of patients in clinical studies and was the most common reason for discontinuation. 3, 4
Standard Escalation Protocol:
- Weeks 1-2: Lamotrigine 25 mg daily 2
- Weeks 3-4: Increase to 50 mg daily 2
- Weeks 5-6: Increase to 100 mg daily (can give as 50 mg twice daily) 2
- Weeks 7-8: Increase to target dose of 200 mg daily 3, 2
The mean effective dose in bipolar II patients is approximately 200 mg/day, which showed significant improvement in depressive symptoms without mood destabilization. 3, 2
Critical Safety Consideration:
- Slow dosage escalation is essential for good tolerability and rash prevention 2
- Monitor closely for any rash development, particularly during the first 8 weeks 3, 4
- If rash develops, discontinue lamotrigine immediately 3
Divalproex Discontinuation Strategy
Do not begin tapering divalproex until lamotrigine reaches at least 100-200 mg daily (weeks 5-8), ensuring adequate mood stabilization coverage throughout the transition. 1, 5
Divalproex Taper Protocol:
- Maintain divalproex 1000 mg/day during entire lamotrigine titration (weeks 1-8) 1, 5
- After week 8: Begin reducing divalproex by 250-500 mg every 1-2 weeks 1
- Monitor serum valproate levels if tapering more rapidly to ensure controlled descent 1
- Total taper duration: 2-4 weeks after lamotrigine reaches therapeutic dose 1
Clinical Monitoring During Transition
Depression Monitoring:
Lamotrigine demonstrates superior efficacy for bipolar depression compared to mania, with 48-56% of patients showing marked response in controlled trials. 2, 4 This makes it particularly appropriate for bipolar II disorder, which is characterized by predominant depressive episodes. 3
Mood Destabilization Risk:
Lamotrigine does not precipitate mania or destabilize mood during treatment of bipolar depression, unlike traditional antidepressants. 2 However, maintain vigilance during the divalproex taper, as removing antimanic coverage could theoretically increase hypomanic risk. 5
Assessment Schedule:
- Weekly visits during first 8 weeks for rash surveillance 3, 4
- Biweekly visits during divalproex taper 1
- Use Hamilton Depression Rating Scale (HDRS-17) and Clinical Global Impression for Bipolar Disorder (CGI-BP-M) to track response 3
Common Pitfalls to Avoid
Titration Errors:
- Never accelerate lamotrigine titration beyond the recommended schedule, even if the patient is doing well—this dramatically increases rash risk 2, 4
- Do not start divalproex taper prematurely before lamotrigine reaches therapeutic levels, as this creates a window of inadequate mood stabilization 5
Drug Interaction Consideration:
Valproate actually increases lamotrigine levels by approximately 2-fold through enzyme inhibition, so the standard titration schedule already accounts for this interaction when used as combination therapy. 6 After divalproex discontinuation, lamotrigine levels may decrease, but dose adjustment is typically not needed if the patient has reached 200 mg daily. 6
Tolerability Issues:
The most common adverse events with lamotrigine are dizziness, tremor, somnolence, headache, and nausea, occurring in addition to rash concerns. 4 These are generally mild and resolve with continued treatment. 2
Expected Timeline and Outcomes
Total transition period: 10-12 weeks (6-8 weeks lamotrigine titration + 2-4 weeks divalproex taper) 1, 2
In clinical studies of bipolar II patients, 67% showed significant improvement in depressive symptoms with lamotrigine, with response typically evident by week 3 of therapeutic dosing. 3, 2 The combination of lamotrigine plus divalproex during the overlap period is well-tolerated and may provide enhanced efficacy during transition. 6